Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

- PMLiVE

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

First new drug for the disease in the EU since 2010

- PMLiVE

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

Met key primary and secondary trial endpoints

- PMLiVE

Roche’s Soliris rival satralizumab scores in phase 3 study

Therapy has been filed in US and Europe with decisions expected in 2020

- PMLiVE

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

- PMLiVE

AstraZeneca wins FDA approval for Calquence in chronic lymphoma

Takes the fight to AbbVie and J&J's lymphoma rival Imbruvica

- PMLiVE

Myovant preps US filing for relugolix in prostate cancer

Takeda-partnered drug had 97% response rate in advanced prostate cancer

- PMLiVE

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Sanofi Genzyme’s Lemtrada and Pfizer's Xeljanz receive label restrictions

- PMLiVE

AbbVie sells $30bn of bonds ahead of Allergan merger

Will use net proceeds to fund cash consideration due to shareholders

Novartis building

Novartis’ Cosentyx misses the mark in Humira head-to-head

Narrowly missed statistical significance for superiority

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links